<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DUEXIS- ibuprofen and famotidine tablet, coated </strong><br>Horizon Pharma Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use DUEXIS<span class="Sup">®</span> safely and effectively. See full prescribing information for DUEXIS. <br><br> DUEXIS (ibuprofen and famotidine) tablets, for oral use<br> Initial U.S. Approval: 2011</div>
<div class="Warning">
<div>
<h1 class="Warning">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</h1>
<h1 class="Warning">
<span class="Italics">See full prescribing information for complete boxed warning</span>. 								</h1>
<ul>
<li><span class="Bold">Ibuprofen, a component of DUEXIS, may increase the risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. Risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">DUEXIS is contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery. (<a href="#S4">4</a>, <a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">NSAIDs, including ibuprofen, a component of DUEXIS, increase the risk of serious gastrointestinal (GI) adverse reactions including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. Reactions can occur at any time without warning symptoms. Elderly patients are at greater risk. (<a href="#S5.4">5.4</a>)</span></li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div class="Warning">
<div>
<h1 class="Warning">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</h1>
<h1 class="Warning">
<span class="Italics">See full prescribing information for complete boxed warning</span>. 								</h1>
<ul>
<li><span class="Bold">Ibuprofen, a component of DUEXIS, may increase the risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. Risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">DUEXIS is contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery. (<a href="#S4">4</a>, <a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">NSAIDs, including ibuprofen, a component of DUEXIS, increase the risk of serious gastrointestinal (GI) adverse reactions including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. Reactions can occur at any time without warning symptoms. Elderly patients are at greater risk. (<a href="#S5.4">5.4</a>)</span></li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">DUEXIS, a combination of the NSAID ibuprofen and the histamine H<span class="Sub">2</span>-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> and to decrease the risk of developing upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcers</span>, which in the clinical trials was defined as a gastric and/or <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span>. Controlled trials do not extend beyond 6 months. (<a href="#S1">1</a>)   </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul><li>One DUEXIS tablet administered orally three times per day (<a href="#S2">2</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Tablets: 800 mg ibuprofen and 26.6 mg famotidine (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> after taking aspirin or other NSAIDs (<a href="#S4">4</a>)</li>
<li>Use during the perioperative period in the setting of coronary artery bypass graft surgery (<a href="#S4">4</a>)</li>
<li>Starting at 30 weeks gestation, DUEXIS should not be used by pregnant women as premature closure of the ductus arteriosus in the fetus may occur. (<a href="#S4">4</a>)</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other H<span class="Sub">2</span>-receptor antagonists (<a href="#S4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>:  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> can occur with NSAID treatment; monitor blood pressure closely during treatment with DUEXIS. (<a href="#S5.2">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>:  <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> can occur with NSAID treatment; use DUEXIS with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#S5.3">5.3</a>)</li>
<li>Active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>:  Active and clinically significant <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from any source can occur; discontinue DUEXIS if active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs (<a href="#S5.5">5.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">Renal Injury</span>:  Long-term administration of NSAIDs can result in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>; use DUEXIS with caution in patients at risk (e.g., the elderly, those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver impairment, and those taking diuretics or ACE inhibitors). (<a href="#S5.6">5.6</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>:  <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> may occur in patients with the aspirin triad or in patients without prior exposure to DUEXIS; discontinue DUEXIS immediately if an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs. (<a href="#S5.8">5.8</a>)</li>
<li>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>:  Includes <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, which can be fatal; discontinue DUEXIS if <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other signs of local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> occur. (<a href="#S5.9">5.9</a>)</li>
<li>Hepatic Injury:  Hepatic injury ranging from transaminase elevations to <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> can occur; discontinue DUEXIS immediately if abnormal liver tests persist or worsen, if clinical signs and symptoms of liver disease develop or if systemic manifestations occur. (<a href="#S5.11">5.11</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥1% and greater than ibuprofen alone) are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Horizon Pharma USA, Inc. at (1-866-479-6742) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch<span class="Italics">.</span></span> </p>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Warfarin-type anticoagulants:  Concomitant use of NSAIDs and anticoagulants (e.g., warfarin) increases the risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#S7.1">7.1</a>) </li>
<li>Aspirin:  Concomitant administration with other NSAIDs, including aspirin, may increase the risk of adverse reactions, including GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. (<a href="#S7.2">7.2</a>)</li>
<li>ACE-inhibitors and diuretics: Ibuprofen, a component of DUEXIS, may reduce the effectiveness of these drugs (<a href="#S7.3">7.3</a>, <a href="#S7.4">7.4</a>)</li>
<li>Lithium:  Ibuprofen, a component of DUEXIS, may increase lithium levels (<a href="#S7.5">7.5</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li>Nursing mothers:  Use with caution, as it is not known if ibuprofen is excreted in human milk and famotidine is excreted in human milk. (<a href="#S8.3">8.3</a>)</li></ul></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING:  RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Cardiovascular Thrombotic Events</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Risk of Gastrointestinal Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	<span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">Renal Injury</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 	<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> </a></h2>
<h2><a href="#section-5.8" class="toc">5.8	<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9	<span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10	Pregnancy </a></h2>
<h2><a href="#section-5.11" class="toc">5.11	Hepatic Injury</a></h2>
<h2><a href="#section-5.12" class="toc">5.12	<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13	Inhibition of Platelet Aggregation</a></h2>
<h2><a href="#section-5.14" class="toc">5.14	Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-5.15" class="toc">5.15	Concomitant NSAID Use</a></h2>
<h2><a href="#section-5.16" class="toc">5.16	<span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span></a></h2>
<h2><a href="#section-5.17" class="toc">5.17	Corticosteroid Treatment</a></h2>
<h2><a href="#section-5.18" class="toc">5.18	Masking of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></a></h2>
<h2><a href="#section-5.19" class="toc">5.19		<span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual Disturbances</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Warfarin-Type Anticoagulants</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Aspirin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	ACE-Inhibitors</a></h2>
<h2><a href="#section-7.4" class="toc">7.4	Diuretics</a></h2>
<h2><a href="#section-7.5" class="toc">7.5	Lithium</a></h2>
<h2><a href="#section-7.6" class="toc">7.6	Methotrexate</a></h2>
<h2><a href="#section-7.7" class="toc">7.7	Selective Serotonin Reuptake Inhibitors (SSRIs)</a></h2>
<h2><a href="#section-7.8" class="toc">7.8	Cholestyramine</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING:  RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<p class="First"><span class="Bold Underline">Cardiovascular Risk</span></p>
<ul>
<li><span class="Bold">NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</span></li>
<li><span class="Bold">NSAIDs, including DUEXIS, are contraindicated for treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>].</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2"></a><p></p>
<p class="First"><span class="Bold Underline">Gastrointestinal Risk</span></p>
<ul><li><span class="Bold">NSAIDs cause an increased risk of serious gastrointestinal adverse reactions including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These reactions can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events [<span class="Italics">see <a href="#S5.4">Warnings and Precautions (5.4)</a></span>].</span></li></ul>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Carefully consider the potential benefits and risks of DUEXIS and other treatment options before deciding to use DUEXIS. Use the shortest duration consistent with individual patient treatment goals [<span class="Italics">see <a href="#S5">Warnings and Precautions (5)</a>, <a href="#S7">Drug Interactions (7)</a> and <a href="#S8">Use in Specific Populations (8)</a></span>].</p>
<p>DUEXIS, a combination of the NSAID ibuprofen and the histamine H<span class="Sub">2</span>-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> and to decrease the risk of developing upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcers</span>, which in the clinical trials was defined as a gastric and/or <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span>. Controlled trials do not extend beyond 6 months. <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a> and <a href="#S8.5">Use in Specific Populations (8.5)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended daily dose of DUEXIS (ibuprofen and famotidine) 800 mg/26.6 mg is a single tablet administered orally three times per day.</p>
<p>DUEXIS tablets should be swallowed whole, and should not be cut to supply a lower dose. Do not chew, divide, or crush tablets.</p>
<p>Patients should be instructed that if a dose is missed, it should be taken as soon possible. However, if the next scheduled dose is due, the patient should not take the missed dose, and should be instructed to take the next dose on time. Patients should be instructed not to take 2 doses at one time to make up for a missed dose.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">DUEXIS (ibuprofen and famotidine) tablets, 800 mg/26.6 mg, are light blue, oval, biconvex, film-coated tablets debossed with "HZT" on one side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<ul class="Disc">
<li>DUEXIS should not be given to patients who have   experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> after taking aspirin   or other NSAIDs. Severe, rarely fatal, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> with NSAIDs have been   reported in such patients [<span class="Italics">see <a href="#S5.7">Warnings and Precautions (5.7</a>, <a href="#S5.12">5.12</a>)</span>   and <span class="Italics"><a href="#S7.2">Drug Interactions (7.2)</a></span>].</li>
<li>DUEXIS is contraindicated for the treatment of   perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG)   surgery [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a></span>].</li>
<li>DUEXIS is contraindicated in patients in late stages of  pregnancy [<span class="Italics">see <a href="#S5.9">Warnings and Precautions (5.9)</a></span>].</li>
<li>DUEXIS should not be administered to patients with a   history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other H<span class="Sub">2</span>-receptor antagonists. Cross   sensitivity with other H<span class="Sub">2</span>-receptor antagonists has been   observed.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Cardiovascular Thrombotic Events</h2>
<p class="First">Clinical trials of several COX-2 selective and nonselective NSAIDs, including ibuprofen, which is a component of DUEXIS tablets, of up to 3 years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.</p>
<p>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious GI events [<span class="Italics">see <a href="#S5.13">Warnings and Precautions (5.13)</a></span>].</p>
<p>Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10-14 days following CABG surgery found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> [<span class="Italics">see <a href="#S4">Contraindications (4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">NSAIDs, including ibuprofen, which is a component of DUEXIS tablets, can lead to onset of new <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or worsening of pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including DUEXIS, should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy [<span class="Italics">see <a href="#S7.1">Drug Interactions (7.1</a>, <a href="#S7.4">7.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients taking NSAIDs. DUEXIS should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Risk of Gastrointestinal Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</h2>
<p class="First">NSAIDs, including ibuprofen, which is a component of DUEXIS tablets, can cause serious gastrointestinal (GI) adverse reactions including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse reactions can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3-6 months, and in about 2-4% of patients treated for 1 year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk. NSAIDs, including DUEXIS, should be prescribed with extreme caution in those with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients with a prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> who use NSAIDs have a greater than 10-fold increased risk for developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> compared to patients treated with neither of these risk factors. Other factors that increase the risk of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with NSAIDs, including DUEXIS, include concomitant use of oral corticosteroids, anticoagulants, antiplatelet drugs (including low-dose aspirin), longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI reactions are in elderly or debilitated patients, and, therefore, special care should be taken in treating this population with DUEXIS.</p>
<p>To minimize the potential risk for an adverse GI reaction in patients treated with an NSAID, the shortest possible duration should be used. Patients and physicians should remain alert for signs and symptoms of GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse reaction is suspected. This should include discontinuation of the NSAID until a serious GI adverse reaction is ruled out. For high-risk patients, alternate therapies that do not involve NSAIDs should be considered.</p>
<p>Epidemiological studies of the case-control and cohort design have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. In two studies, concurrent use of an NSAID, COX-2 inhibitor, or aspirin potentiated the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> [<span class="Italics">see <a href="#S7.2">Drug Interactions (7.2</a>, <a href="#S7.7">7.7</a>)</span>]. Although these studies focused on upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> at other sites cannot be ruled out.</p>
<p>NSAIDs should be given with care to patients with a history of <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> (<span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, Crohn's disease) as their condition may be exacerbated.</p>
<p>Because serious GI tract <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physicians should monitor for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients on long-term treatment with NSAIDs should have their complete blood count (CBC) and chemistry profile checked periodically.</p>
<p>Symptomatic response to therapy with DUEXIS does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">When active and clinically significant <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from any source occurs in patients receiving DUEXIS, the treatment should be withdrawn. Patients with initial hemoglobin values of 10 g or less who are to receive long-term therapy should have hemoglobin values determined periodically.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	<span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">Renal Injury</span></h2>
<p class="First">Long-term administration of NSAIDs, including ibuprofen, which is a component of DUEXIS tablets, has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors, and the elderly. If clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and/or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>) and symptoms consistent with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> develop, DUEXIS should be discontinued. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a> and <a href="#S8.6">Use in Specific Populations (8.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 	<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> </h2>
<p class="First">Central nervous system (CNS) adverse effects including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> have been reported with famotidine in patients with moderate (creatinine clearance &lt;50 mL/min) and severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (creatinine clearance &lt;10 mL/min), and the dosage of the famotidine component in DUEXIS is fixed. Therefore, DUEXIS is not recommended in patients with creatinine clearance &lt; 50 mL/min.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> may occur in patients without known prior exposure to ibuprofen, which is a component of DUEXIS tablets. DUEXIS should not be given to patients with the aspirin triad. This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs [<span class="Italics">see <a href="#S4">Contraindications(4)</a> and <a href="#S5.12">Warnings and Precautions (5.12)</a></span>]. Emergency help should be sought in cases where <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, which may have a fatal outcome, occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	<span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">NSAIDs, including ibuprofen, which is a component of DUEXIS tablets, can cause serious skin adverse reactions such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S6">Adverse Reactions (6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10	Pregnancy </h2>
<p class="First">Starting at 30 weeks gestation, DUEXIS should be avoided by pregnant women because it may cause premature closure of the ductus arteriosus [<span class="Italics">see <a href="#S4">Contraindications (4)</a> and <a href="#S8.1">Use in Specific Population (8.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11	Hepatic Injury</h2>
<p class="First">Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs, including ibuprofen, which is a component of DUEXIS tablets. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT) or <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST) (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span>, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, some of them with fatal outcomes have been reported.</p>
<p>A patient with symptoms and/or signs suggesting liver dysfunction, or with abnormal liver test values, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with DUEXIS. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.), DUEXIS should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12	<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> is sometimes seen in patients receiving NSAIDs, including ibuprofen which is a component of DUEXIS tablets. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including DUEXIS, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13	Inhibition of Platelet Aggregation</h2>
<p class="First">NSAIDs inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving DUEXIS who may be adversely affected by alterations in platelet function, such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants, should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.14"></a><a name="section-5.14"></a><p></p>
<h2>5.14	Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, which can be fatal. Since cross reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and NSAIDs has been reported in such aspirin-sensitive patients, DUEXIS should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.15"></a><a name="section-5.15"></a><p></p>
<h2>5.15	Concomitant NSAID Use</h2>
<p class="First">DUEXIS contains ibuprofen as one of its active ingredients. It should not be used with other ibuprofen-containing products.</p>
<p>The concomitant use of NSAIDs, including aspirin, with DUEXIS may increase the risk of adverse events [<span class="Italics">see <a href="#S6">Adverse Reactions (6)</a>, <a href="#S7.2">Drug Interactions (7.2)</a>, and <a href="#S14">Clinical Studies (14)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.16"></a><a name="section-5.16"></a><p></p>
<h2>5.16	<span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> has been observed on rare occasions in patients on ibuprofen, which is a component of DUEXIS. Although it is probably more likely to occur in patients with <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> (SLE) and related connective tissue diseases, it has been reported in patients who do not have an underlying chronic disease. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> develop in a patient on DUEXIS, the possibility of its being related to ibuprofen should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.17"></a><a name="section-5.17"></a><p></p>
<h2>5.17	Corticosteroid Treatment</h2>
<p class="First">DUEXIS cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids and the patient should be observed closely for any evidence of adverse effects, including <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> and exacerbation of symptoms of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.18"></a><a name="section-5.18"></a><p></p>
<h2>5.18	Masking of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></h2>
<p class="First">The pharmacological activity of DUEXIS in reducing <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, noninflammatory painful conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.19"></a><a name="section-5.19"></a><p></p>
<h2>5.19		<span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual Disturbances</span></h2>
<p class="First">Blurred and/or diminished vision, scotomata, and/or changes in color vision have been reported. If a patient develops such complaints while receiving DUEXIS, the drug should be discontinued, and the patient should have an ophthalmologic examination which includes central visual fields and color vision testing.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in the labeling:</p>
<ul class="Disc">
<li>Cardiovascular events [<span class="Italics">see <a href="#BOX">Boxed Warning</a> and <a href="#S5.1">Warnings   and Precautions (5.1)</a></span>]</li>
<li>Gastrointestinal effects [<span class="Italics">see <a href="#BOX">Boxed Warning</a> and   <a href="#S5.4">Warnings and Precautions (5.4)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">Renal injury</span> [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>  [<span class="Italics">see <a href="#S5.7">Warnings and Precautions (5.7)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> [<span class="Italics">see <a href="#S5.8">Warnings and Precautions (5.8)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin reactions</span> [<span class="Italics">see <a href="#S5.9">Warnings and Precautions (5.9)</a></span>]</li>
<li>Corticosteroid treatment [<span class="Italics">see <a href="#S5.17">Warnings and Precautions   (5.17)</a></span>]</li>
<li>Masking of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> [<span class="Italics">see <a href="#S5.18">Warnings   and Precautions (5.18)</a></span>]</li>
<li>Hepatic injury [<span class="Italics">see <a href="#S5.11">Warnings and Precautions (5.11)</a></span>]</li>
<li>Hematological effects [<span class="Italics">see <a href="#S5.13">Warnings and Precautions (5.13)</a></span>]</li>
<li>Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> [<span class="Italics">see <a href="#S5.14">Warnings and Precautions (5.14)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> [<span class="Italics">see <a href="#S5.16">Warnings and Precautions (5.16)</a></span>]</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The safety of DUEXIS was evaluated in 1022 patients in controlled clinical studies, including 508 patients treated for at least 6 months and 107 patients treated for approximately 1 year. Patients treated with DUEXIS ranged in age from 39 to 80 years (median age 55 years), with 67% female, 79% Caucasian, 18% African-American, and 3% other races. Two randomized, active-controlled clinical studies (Study 301 and Study 303) were conducted for the reduction of the risk of development of ibuprofen-associated, upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcers</span> in patients who required use of ibuprofen, which included 1022 patients on DUEXIS and 511 patients on ibuprofen alone. Approximately 15% of patients were on low-dose aspirin. Patients were assigned randomly, in a 2:1 ratio, to treatment with either DUEXIS or ibuprofen 800 mg three times a day for 24 consecutive weeks</p>
<p>Three serious cases of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> were observed in patients treated with DUEXIS in the two controlled clinical trials. All three patients recovered to baseline levels after discontinuation of DUEXIS. Additionally, increases in serum creatinine were observed in both treatment arms in the two clinical studies. Many of these patients were taking concomitant diuretics and/or angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers. There were patients with a normal baseline serum creatinine level who developed abnormal values in the controlled trials as presented in Table 1.</p>
<table width="80%">
<caption><span>Table 1:  Shift table of serum creatinine, normal<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> to abnormal<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a> in controlled studies</span></caption>
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center" colspan="2">Study 301</th>
<th class="Rrule" align="center" colspan="2">Study 303</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Baseline</th>
<th class="Rrule" align="center">Post-Baseline<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</th>
<th class="Rrule" align="center">DUEXIS<br>N=414<br>% (n)</th>
<th class="Rrule" align="center">Ibuprofen<br>N=207<br>% (n)</th>
<th class="Rrule" align="center">DUEXIS<br>N=598<br>% (n)</th>
<th class="Rrule" align="center">Ibuprofen<br>N=296<br>% (n)</th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>serum creatinine normal range is 0.5 – 1.4 mg/dL or 44-124 micromol/L</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>serum creatinine &gt;1.4 mg/dL</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>At any point after baseline level</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="center">Normal<a href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">Abnormal<a href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">4% (17)</td>
<td class="Rrule" align="center">2% (4)</td>
<td class="Rrule" align="center">2%(15)</td>
<td class="Rrule" align="center">4% (12)</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Most Commonly Reported Adverse Reactions</span></p>
<p>The most common adverse reactions (≥2%), from pooled data from the two controlled studies are presented in Table 2.</p>
<table width="90%">
<caption><span>Table  2:  Incidence of Adverse Reactions in Controlled Studies</span></caption>
<col align="left" valign="bottom" width="60%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2"></th>
<th class="Botrule Rrule" align="center">DUEXIS<br>N=1022</th>
<th class="Botrule Rrule" align="center">Ibuprofen<br>N=511</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">%</th>
<th class="Rrule" align="center">%</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="3">DUEXIS (ibuprofen and famotidine) tablets 800 mg/26.6 mg administered orally three times per day.</td></tr>
<tr class="Last"><td align="left" colspan="3">Ibuprofen 800 mg administered orally three times per day.</td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Blood and lymphatic system disorders</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal reflux disease</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">Stomach discomfort</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">General disorders and administration site conditions</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">2</td>
</tr>
</tbody>
</table>
<p>In controlled clinical studies, the discontinuation rate due to adverse events for patients receiving DUEXIS and ibuprofen alone were similar. The most common adverse reactions leading to discontinuation from DUEXIS therapy were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (0.9%) and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span> (0.9%).</p>
<p>There were no differences in types of related adverse reactions seen during maintenance treatment up to 12 months compared to short-term treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Underline">Ibuprofen</span></p>
<p>The following adverse reactions have been identified during post-approval use of ibuprofen. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reports are listed below by body system:</p>
<p><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>: <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
<p>General disorders and administration site conditions: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, drug ineffective, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span></p>
<p>Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span></p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></p>
<p>Psychiatric disorders: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></p>
<p>Renal and urinary disorders: <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">renal failure acute</span></p>
<p>Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>: <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Underline">Famotidine</span></p>
<p>The following adverse reactions have been identified during post-approval use of famotidine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reports are listed below by body system:</p>
<p>Blood and lymphatic system disorders: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
<p>General disorders and administration site conditions: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, condition aggravated, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, drug ineffective, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span></p>
<p>Hepatobiliary disorders: <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">hepatic function abnormal</span></p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>: <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span></p>
<p>Investigations: platelet count decreased, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">hemoglobin decreased</span></p>
<p>Metabolism and nutrition disorders: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p>Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>: <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Co-administration of ibuprofen (800 mg) and famotidine (40 mg) increased ibuprofen C<span class="Sub">max</span> by 15.6% but did not affect its AUC, and increased famotidine AUC and C<span class="Sub">max</span> by 16% and 22%, respectively.</p>
<p>Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested, and no significant effects have been found.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Warfarin-Type Anticoagulants</h2>
<p class="First">Several short-term controlled studies failed to show that ibuprofen significantly affected <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times or a variety of other clotting factors when administered to individuals on coumarin-type anticoagulants. However, because <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> has been reported when ibuprofen and other NSAIDs have been administered to patients on coumarin-type anticoagulants, prescribers should be cautious when administering ibuprofen to patients on anticoagulants. The effects of warfarin and NSAIDs on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that the users of both drugs together have a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than users of either drug alone<span class="Italics"> [see <a href="#S5.4">Warnings and Precautions (5.4</a>, <a href="#S5.14">5.14</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Aspirin</h2>
<p class="First">When ibuprofen, which is a component of DUEXIS tablets, is administered with aspirin, its protein binding is reduced, although the clearance of free ibuprofen is not altered. The clinical significance of this interaction is not known. As with other NSAIDs, the concurrent use of aspirin and DUEXIS may increase the risk of adverse events [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1</a>, <a href="#S5.4">5.4</a>), <a href="#S6">Adverse Reactions (6)</a>, and <a href="#S14">Clinical Studies (14)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	ACE-Inhibitors</h2>
<p class="First">Reports suggest that ibuprofen, a component of DUEXIS, may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking DUEXIS concomitantly with ACE-inhibitors. During concomitant therapy with DUEXIS, the patient should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span><span class="Italics"> [see <a href="#S5.6">Warnings and Precautions (5.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4	Diuretics</h2>
<p class="First">Clinical studies, as well as postmarketing observations, have shown that ibuprofen, which is a component of DUEXIS, can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with DUEXIS, the patient should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a></span>], as well as to assure diuretic efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5	Lithium</h2>
<p class="First">Ibuprofen, which is a component of DUEXIS tablets, produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of 11 normal volunteers. The mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 20% during this period of concomitant ibuprofen drug administration. This effect has been attributed to inhibition of renal prostaglandin synthesis by ibuprofen. Thus, when ibuprofen and lithium are administered concurrently, patients should be observed carefully for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6	Methotrexate</h2>
<p class="First">NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.7"></a><a name="section-7.7"></a><p></p>
<h2>7.7	Selective Serotonin Reuptake Inhibitors (SSRIs)</h2>
<p class="First">There is an increased risk of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> when selective serotonin reuptake inhibitors (SSRIs) are combined with NSAIDs including COX-2 selective inhibitors. Caution should be used when NSAIDs are administered concomitantly with SSRIs [<span class="Italics">see <a href="#S5.4">Warnings and Precautions (5.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.8"></a><a name="section-7.8"></a><p></p>
<h2>7.8	Cholestyramine</h2>
<p class="First">As with other NSAIDs, concomitant administration of cholestyramine can delay the absorption of ibuprofen, a component of DUEXIS.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Underline">Teratogenic Effects</span></p>
<p>Pregnancy Category C. Animal reproduction studies have not been conducted with DUEXIS. Reproductive studies conducted with ibuprofen in rats and rabbits have not demonstrated evidence of developmental abnormalities. Reproductive studies with famotidine have been performed in rats and rabbits at oral doses of up to 2000 and 500 mg/kg/day (approximately 243 and 122 times the recommended human dose, respectively, based on body surface area) and in both species at intravenous (I.V.) doses of up to 200 mg/kg/day, and have revealed no significant evidence of impaired fertility or harm to the fetus due to famotidine. While no direct fetotoxic effects have been observed, sporadic abortions occurring only in mothers displaying marked decreased food intake were seen in some rabbits at oral doses of 200 mg/kg/day (approximately 49 times the recommended human dose based on body surface area) or higher. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response. DUEXIS should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Underline">Nonteratogenic Effects</span></p>
<p>Because of the known effects of NSAIDs on the fetal cardiovascular system (closure of ductus arteriosus), use during late pregnancy should be avoided<span class="Italics"> [see <a href="#S5.10">Warnings and Precautions (5.10)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred. The effects of DUEXIS on labor and delivery in pregnant women are unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether ibuprofen is excreted in human milk.</p>
<p>Famotidine is secreted into breast milk of lactating rats. Transient growth <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> was observed in young rats suckling from mothers treated with maternotoxic doses of at least 300 times the usual human dose of famotidine. Famotidine is detectable in human milk. Because of the potential for serious adverse reactions in nursing infants from DUEXIS, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">The clinical trials primarily enrolled patients less than 65 years of age. Of the 1022 patients in clinical studies of DUEXIS, 18% (249 patients) were 65 years of age or older. Efficacy results in patients who are greater than or equal to 65 years of age are summarized in the CLINICAL STUDIES section [<span class="Italics">see <a href="#S14">Clinical Studies (14)</a>].</span></p>
<p>Famotidine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and adjusting dose interval, and it may be useful to monitor renal function [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a></span>].</p>
<p>As with any NSAIDs, caution should be exercised in treating the elderly (65 years old and older). Experience indicates that geriatric patients may be particularly sensitive to certain adverse effects of NSAIDs. Elderly or debilitated patients seem to tolerate <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> less well when these events do occur. Most spontaneous reports of fatal GI events are in the geriatric population [<span class="Italics">see <a href="#S5.4">Warnings and Precautions (5.4)</a></span>].</p>
<p>Ibuprofen is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Geriatric patients may be at a greater risk for the development of a form of renal toxicity precipitated by reduced prostaglandin formation during administration of NSAIDs [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h2>
<p class="First">In adult patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (creatinine clearance &lt; 50 mL/min), the elimination half-life of famotidine is increased. Since CNS adverse effects have been reported in patients with creatinine clearance &lt; 50 mL/min and the dosage of the famotidine component in DUEXIS is fixed, DUEXIS is not recommended in these patients<span class="Italics"> [see <a href="#S5.7">Warnings and Precautions (5.7)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No data are available with regard to <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of DUEXIS. Findings related to the individual active substances are listed below.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<p class="First"><span class="Underline">Ibuprofen</span></p>
<p>Approximately 1 1/2 hours after the reported ingestion of from 7 to 10 ibuprofen tablets (400 mg), a 19-month-old child weighing 12 kg was seen in the hospital emergency room, apneic and cyanotic, responding only to painful stimuli. This type of stimulus, however, was sufficient to induce respiration. Oxygen and parenteral fluids were given; a greenish-yellow fluid was aspirated from the stomach with no evidence to indicate the presence of ibuprofen. Two hours after ingestion the child's condition seemed stable; she still responded only to painful stimuli and continued to have periods of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> lasting from 5 to 10 seconds. She was admitted to intensive care and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> was administered as well as infusions of dextrose and normal saline. By 4 hours post-ingestion she could be aroused easily, sit by herself, and respond to spoken commands. Blood level of ibuprofen was 102.9 μg/mL approximately 8.5 hours after accidental ingestion. At 12 hours she appeared to be completely recovered.</p>
<p>In two other reported cases where children (each weighing approximately 10 kg) accidentally, acutely ingested approximately 120 mg/kg, there were no signs of acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> or late sequelae. Blood level in one child 90 minutes after ingestion was 700 μg/mL — about 10 times the peak levels seen in absorption-excretion studies.</p>
<p>A 19-year-old male who had taken 8,000 mg of ibuprofen over a period of a few hours complained of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span> was noted. After hospitalization, parenteral hydration and 3 days bed rest, he recovered with no reported sequelae.</p>
<p>In cases of acute overdosage, the stomach should be emptied by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or lavage, though little drug will likely be recovered if more than 1 hour has elapsed since ingestion. Because the drug is acidic and is excreted in the urine, it is theoretically beneficial to administer alkali and induce <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. In addition to supportive measures, the use of oral activated charcoal may help to reduce the absorption and reabsorption of ibuprofen tablets.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<p class="First"><span class="Underline">Famotidine</span></p>
<p>The adverse reactions in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> cases are similar to the adverse reactions encountered in normal clinical experience. Oral doses of up to 640 mg/day have been given to adult patients with pathological hypersecretory conditions with no serious adverse effects. In the event of overdosage, treatment should be symptomatic and supportive. Unabsorbed material should be removed from the GI tract, the patient should be monitored, and supportive therapy should be employed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">DUEXIS (ibuprofen and famotidine) is supplied as a tablet for oral administration which combines the nonsteroidal anti-inflammatory agent, ibuprofen, and the histamine H<span class="Sub">2</span>-receptor antagonist, famotidine.</p>
<p>Ibuprofen is (±)-2-(<span class="Italics">p-</span>isobutylphenyl)propionic acid. Its chemical formula is C<span class="Sub">13</span>H<span class="Sub">18</span>O<span class="Sub">2</span> and molecular weight is 206.28. Ibuprofen is a white powder that is very slightly soluble in water (&lt;1 mg/mL) and readily soluble in organic solvents such as ethanol and acetone. Its structural formula is:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=558b9f26-37b2-423b-932d-25a37afe57ec&amp;name=duexis-01.jpg"></p>
<p>Famotidine is <span class="Italics">N'-</span>(aminosulfonyl)-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propanimidamide. Its chemical formula is C<span class="Sub">8</span>H<span class="Sub">15</span>N<span class="Sub">7</span>O<span class="Sub">2</span>S<span class="Sub">3</span> and molecular weight is 337.45. Famotidine is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow crystalline compound that is freely soluble in glacial acetic acid, slightly soluble in methanol, very slightly soluble in water, and practically insoluble in ethanol. Its structural formula is:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=558b9f26-37b2-423b-932d-25a37afe57ec&amp;name=duexis-02.jpg"></p>
<p>Each DUEXIS tablet contains ibuprofen, USP (800 mg) and famotidine, USP (26.6 mg) and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, purified water, povidone, titanium dioxide, polyethylene glycol, polysorbate 80, polyvinyl alcohol, hypromellose, talc, FD&amp;C Blue #2/Indigo Carmine Aluminum Lake, and FD&amp;C Blue #1/Brilliant Blue FCF Aluminum Lake.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">DUEXIS is fixed-combination tablet of ibuprofen and famotidine</p>
<p>Ibuprofen possesses analgesic and antipyretic activities. Its mode of action, like that of other NSAIDs, is not completely understood, but may be related to prostaglandin synthetase inhibition.</p>
<p>Famotidine is a competitive inhibitor of histamine H<span class="Sub">2</span>-receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output.</p>
<p>Systemic effects of famotidine in the CNS, cardiovascular, respiratory, or endocrine systems were not noted in clinical pharmacology studies. Also, no antiandrogenic effects were noted. Serum hormone levels, including prolactin, cortisol, thyroxine (T<span class="Sub">4</span>), and testosterone, were not altered after treatment with famotidine.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">No pharmacodynamic studies were conducted.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption</span></p>
<p>Ibuprofen and famotidine are rapidly absorbed after a single dose administration of DUEXIS. Mean C<span class="Sub">max</span> values for ibuprofen are 45 µg/mL and are reached approximately 1.9 hours after oral administration of DUEXIS. The C<span class="Sub">max</span> and AUC<span class="Sub">0-24hours</span> values for the 800 mg of ibuprofen contained in a DUEXIS tablet are bioequivalent to the values for 800 mg of ibuprofen administered alone. C<span class="Sub">max</span> values for famotidine were 61 ng/mL and are reached at approximately 2 hours after oral administration of DUEXIS.</p>
<p>A high-fat meal reduced famotidine C<span class="Sub">max</span> and AUC by approximately by 15% and 11%, respectively, and reduced ibuprofen AUC by approximately 14% but did not change C<span class="Sub">max</span>. Food delayed famotidine T<span class="Sub">max</span> and ibuprofen T<span class="Sub">max</span> by approximately 1 hour and 0.2 hour, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>Ibuprofen is extensively bound to plasma proteins.</p>
<p>Fifteen to 20% of famotidine in plasma is protein bound.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span></p>
<p>The only metabolite of famotidine identified in man is the S-oxide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Excretion</span></p>
<p>Ibuprofen is eliminated from the systemic circulation with a mean half-life (t<span class="Sub">1/2</span>) value of 2 hours following administration of a single dose of DUEXIS.</p>
<p>Ibuprofen is rapidly metabolized and eliminated in the urine. The excretion of ibuprofen is virtually complete 24 hours after the last dose.</p>
<p>Studies have shown that following ingestion of the drug, 45% to 79% of the dose was recovered in the urine within 24 hours as metabolite A (25%), (+)-2-[p-(2-hydroxymethyl-propyl) phenyl] propionic acid and metabolite B (37%), (+)-2-[p-(2-carboxypropyl)phenyl] propionic acid; the percentages of free and conjugated ibuprofen were approximately 1% and 14%, respectively.</p>
<p>Famotidine is eliminated from the systemic circulation with a mean t<span class="Sub">1/2</span> value of 4 hours following administration of a single dose of DUEXIS.</p>
<p>Famotidine is eliminated by renal (65-70%) and metabolic (30-35%) routes. Renal clearance is 250-450 mL/min, indicating some tubular excretion. Twenty-five to 30% of an oral dose and 65-70% of an intravenous dose are recovered in the urine as unchanged compound.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Underline">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1"></a><p></p>
<p class="First">Gender:  The effects of gender on the pharmacokinetics of ibuprofen or famotidine after administration of DUEXIS have not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2"></a><p></p>
<p class="First">Age:  The effects of age on the pharmacokinetics of ibuprofen or famotidine after administration of DUEXIS have not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.3"></a><p></p>
<p class="First">Pediatrics:  The pharmacokinetics of ibuprofen or famotidine after administration of DUEXIS have not been evaluated in a pediatric population considering the doses of ibuprofen and famotidine in DUEXIS are targeted for use in an adult population.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.4"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>:  There is a close relationship between creatinine clearance values and the elimination t<span class="Sub">1/2</span> of famotidine, which is a component of DUEXIS tablets. In patients with creatinine clearance &lt;50 mL/min, the elimination t<span class="Sub">1/2</span> of famotidine is increased and may exceed 20 hours. Therefore, DUEXIS is not recommended in patients with creatinine clearance &lt; 50 mL/min. [<span class="Italics">see <a href="#S5.7">Warnings and Precautions (5.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.5"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>:  The effects of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of ibuprofen or famotidine after administration of DUEXIS have not been evaluated [<span class="Italics">see <a href="#S5.11">Warnings and Precautions (5.11)</a></span>].</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies to evaluate the potential effects of DUEXIS on carcinogenicity, mutagenicity, or impairment of fertility have not been conducted.</p>
<p>In a 106-week study in rats and a 92-week study in mice, famotidine was given at oral doses of up to 2000 mg/kg/day (approximately 122 and 243 times the recommended human dose, respectively, based on body surface area). There was no evidence of carcinogenic potential for famotidine.</p>
<p>Famotidine was negative in the microbial mutagen test (Ames test) using <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> and <span class="Italics">Escherichia coli</span> with or without rat liver enzyme activation at concentrations up to 10,000 µg/plate. In <span class="Italics">in vivo</span> mouse micronucleus test and a chromosomal aberration test with famotidine, no evidence of a mutagenic effect was observed.</p>
<p>In studies of famotidine in rats at oral doses of up to 2000 mg/kg/day (approximately 243 times the recommended human dose, based on body surface area), fertility and reproductive performance were not affected.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Two multicenter, double-blind, active-controlled, randomized, 24-week studies of DUEXIS were conducted in patients who were expected to require daily administration of an NSAID for at least the coming 6 months for conditions such as the following: <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, chronic <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">low back pain</span>, chronic regional <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> syndrome, and chronic soft tissue <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Patients were assigned randomly, in approximately a 2:1 ratio, to treatment with either DUEXIS or ibuprofen (800 mg) three times a day for 24 consecutive weeks. A total of 1533 patients were enrolled and ranged in age from 39 to 80 years (median age 55 years) with 68% females. Race was distributed as follows: 79% Caucasian, 18% African-American, and 3% Other. Approximately 15% of the patients in Studies 301 and 303 were taking concurrent low-dose aspirin (less than or equal to 325 mg daily), 18% were 65 years of age or older, and 6% had a history of previous upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span>. Although H. pylori status was negative at baseline, H. pylori status was not reassessed during the trials.</p>
<p>Studies 301 and 303 compared the incidence of upper gastrointestinal (gastric and/or duodenal) <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> formation in a total 930 patients taking DUEXIS (ibuprofen and famotidine) and 452 patients taking ibuprofen only, either as a primary or secondary endpoint. In both trials, DUEXIS was associated with a statistically significantly reduction in the risk of developing upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcers</span> compared to taking ibuprofen only during the 6 month study period.   The data are presented below in Tables 3 and 4. Two analyses for each endpoint were conducted. In one analysis patients who terminated early, without an endoscopic evaluation within 14 days of their last dose of study drug, were classified as not having an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>. In the second analysis, those patients were classified as having an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>. Both analyses exclude patients who terminated study prior to the first scheduled endoscopy at 8 weeks.</p>
<table width="90%">
<caption><span>Table 3:  Overall Incidence Rates of Patients Who Developed at Least One Upper Gastrointestinal or <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcer</span> - Study 301</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="24%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">DUEXIS<br>% (n/N)</th>
<th class="Rrule" align="center">Ibuprofen<br>% (n/N)</th>
<th class="Rrule" align="center">
<span class="Italics">P</span>-value<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Cochran-Mantel-Haenszel test</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Classifying early terminated patients as NOT having an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span></dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>Classifying patients who early terminated due to an adverse event, were lost to follow-up, discontinued due to the discretion of the sponsor or the investigator, or did not have an endoscopy performed within 14 days of their last dose of study drug, as having an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Primary endpoint</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a>
</td>
<td class="Rrule" align="center">10.5% (40/380)</td>
<td class="Rrule" align="center">20.0% (38/190)</td>
<td class="Rrule" align="center">0.002</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">22.9% (87/380)</td>
<td class="Rrule" align="center">32.1% (61/190)</td>
<td class="Rrule" align="center">0.020</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Secondary endpoint</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric ulcer</span><a href="#footnote-5" class="Sup">†</a>
</td>
<td class="Rrule" align="center">9.7% (37/380)</td>
<td class="Rrule" align="center">17.9% (34/190)</td>
<td class="Rrule" align="center">0.005</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric ulcer</span><a href="#footnote-6" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">22.4% (85/380)</td>
<td class="Rrule" align="center">30.0% (57/190)</td>
<td class="Rrule" align="center">0.052</td>
</tr>
</tbody>
</table>
<table width="90%">
<caption><span>Table 4: Overall Incidence Rate of Patients Who Developed at Least One Gastric or Upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">Gastrointestinal Ulcer</span> - Study 303</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="24%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">DUEXIS<br>% (n/N)</th>
<th class="Rrule" align="center">Ibuprofen<br>% (n/N)</th>
<th class="Rrule" align="center">
<span class="Italics">P</span>-value<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Cochran-Mantel-Haenszel test </dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>Classifying early terminated patients as NOT having an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span></dd>
<dt><a name="footnote-9" href="#footnote-reference-9">‡</a></dt>
<dd>Classifying patients who early terminated due to an adverse event, were lost to follow-up, discontinued due to the discretion of the sponsor or the investigator, or did not have an endoscopy performed within 14 days of their last dose of study drug, as having an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Primary endpoint</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric ulcer</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="center">8.7% (39/447)</td>
<td class="Rrule" align="center">17.6% (38/216)</td>
<td class="Rrule" align="center">0.0004</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric ulcer</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">17.4% (78/447)</td>
<td class="Rrule" align="center">31.0% (67/216)</td>
<td class="Rrule" align="center">&lt;0.0001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Secondary endpoint</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span><a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="center">10.1% (45/447)</td>
<td class="Rrule" align="center">21.3% (46/216)</td>
<td class="Rrule" align="center">&lt;0.0001</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span><a href="#footnote-9" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">18.6% (83/447)</td>
<td class="Rrule" align="center">34.3% (74/216)</td>
<td class="Rrule" align="center">&lt;0.0001</td>
</tr>
</tbody>
</table>
<p>Subgroup analyses of patients who used low-dose aspirin (less than or equal to 325 mg daily), were 65 years and older, or had a prior history of <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span> are summarized as follows:</p>
<p>Of the 1022 patients in clinical studies of DUEXIS, 15% (213 patients) used low-dose aspirin and the results were consistent with the overall findings of the study. In these clinical studies 16% of patients who used low-dose aspirin who were treated with DUEXIS developed an upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span> compared to 35% of those patients who received only ibuprofen. </p>
<p>The clinical trials primarily enrolled patients less than 65 years without a prior history of <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span>. Of the 1022 patients in clinical studies of DUEXIS, 18% (249 patients) were 65 years of age or older. In these clinical studies, 23% of patients 65 years of age and older who were treated with DUEXIS developed an upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span> compared to 27% of those patients who received only ibuprofen. [<span class="Italics">see<a href="#S8.5"> Use in Specific Populations (8.5)</a>] </span></p>
<p>Of the 1022 patients in clinical studies of DUEXIS, 6% had a prior history of <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span>. In these clinical studies, 25% of patients with a prior history of <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span> who were treated with DUEXIS developed an upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcer</span> compared to 24% of those patients who received only ibuprofen.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">DUEXIS (ibuprofen and famotidine) tablets, 800 mg/26.6 mg, are light blue, oval, biconvex, film-coated tablets debossed with "HZT" on one side and supplied as:</p>
<table width="80%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last Toprule">
<th align="left"><span class="Underline">NDC Number</span></th>
<th align="left"><span class="Underline">Size</span></th>
</tr></thead>
<tbody><tr class="Botrule First Last Toprule">
<td align="left">75987-010-03</td>
<td align="left">Bottle of 90 tablets</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). [See USP Controlled Room Temperature]</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">"See <a href="#MEDGUIDE">FDA-approved patient labeling (Medication Guide)</a>"</p>
<p>Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide.</p>
<ul class="Disc">
<li>DUEXIS, like other NSAIDs, may cause serious CV side   effects, such as MI or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and   even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> [<span class="Italics">see<a href="#S5.1"> Warnings and Precautions (5.1)</a></span>].</li>
<li>DUEXIS, like other NSAIDs, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and,   rarely, serious GI side effects, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may   result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> [<span class="Italics">see <a href="#S5.4">Warnings and Precautions   (5.4)</a></span>].</li>
<li>DUEXIS, like other NSAIDs, can cause serious skin side   effects such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens Johnson Syndrome</span>, and Toxic   <span class="product-label-link" type="condition" conceptid="4142366" conceptname="Ten">epidermal necrolysis</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients   should be advised to stop the drug immediately if they develop any type of   <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and contact their physicians as soon as possible.</li>
<li>Patients should be monitored for development of   <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> (e.g., <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and/or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>). If   these occur, patients should be instructed to stop therapy and seek   immediate medical therapy.</li>
<li>DUEXIS is not recommended in patients with creatinine   clearance &lt; 50 mL/min because of the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and other   CNS effect.</li>
<li>Patients should promptly report signs or symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> to their physicians. </li>
<li>Patients should be informed of the warning signs and   symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>,   <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and "flu-like"   symptoms). If these occur, patients should be instructed to stop therapy   and seek immediate medical therapy.</li>
<li>Patients should be informed of the signs of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>   (e.g. <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). If these   occur, patients should be instructed to seek immediate emergency help [<span class="Italics">see   <a href="#S5.7">Warnings and Precautions (5.7)</a></span>].</li>
<li>Patients should be informed that in late pregnancy, as   with other NSAIDs, DUEXIS should be avoided because it may cause premature   closure of the ductus arteriosus.</li>
<li>DUEXIS tablets should be swallowed whole, and should not   be cut to supply a lower dose. Do not chew, divide, or crush tablets [<span class="Italics">see   <a href="#S2">Dosage and Administration (2)</a></span>].</li>
<li>Patients should be   instructed that if a dose is missed, it should be taken as soon possible. However,   if the next schedule dose is due, the patient should not take the missed   dose, and should be instructed to take the next dose on time. Patients   should be instructed not to take 2 doses at one time to make up for a   missed dose.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured for:<br> Horizon Pharma USA, Inc.<br> 520 Lake Cook Road, Suite 520<br> Deerfield, IL 60015</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="MEDGUIDE"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Medication Guide<br><span class="Underline"> DUEXIS<span class="Sup">®</span></span> (due ex is)<br> (ibuprofen and famotidine)<br> tablets</span></p>
<p>Read this Medication Guide before you start taking DUEXIS and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.</p>
<p><a name="What"></a><span class="Bold">What is the most important information I should know about DUEXIS?</span></p>
<p><span class="Bold">DUEXIS contains ibuprofen [a nonsteroidal anti-inflammatory drug (NSAID)] and famotidine.  NSAID-containing medicines, such as DUEXIS, may increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span>This chance increases:</p>
<ul>
<li>with longer use of NSAID medicines</li>
<li>in people who have heart disease</li>
</ul>
<p><span class="Bold">NSAID-containing medicines, such as DUEXIS, should never be used right before or after a heart surgery called a coronary artery bypass graft (CABG).</span></p>
<p><span class="Bold">NSAID-containing medicines, such as DUEXIS can cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the stomach and intestines at any time during treatment. <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:</span></p>
<ul>
<li>can happen without warning symptoms</li>
<li>may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></li>
</ul>
<p><span class="Bold">The chance of a person getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> with NSAIDs increases with:</span></p>
<ul>
<li>taking medicines called steroid hormones (corticosteroids) and blood thinners (anticoagulants)</li>
<li>longer use of the NSAID</li>
<li>smoking</li>
<li>drinking alcohol</li>
<li>older age</li>
<li>having poor health</li>
</ul>
<p><span class="Bold">NSAID-containing medicines, such as DUEXIS, should only be used:</span></p>
<ul>
<li>exactly as prescribed</li>
<li>at the lowest dose possible for your treatment</li>
<li>for the shortest time needed</li>
</ul>
<p><span class="Bold">What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<p>NSAID medicines are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditions such as:</p>
<ul class="Disc"><li>different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> (<span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>)</li></ul>
<p><span class="Bold">Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)?  </span></p>
<p><span class="Bold">Do not take an NSAID medicine: </span></p>
<ul>
<li>If you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with aspirin or any other NSAID medicine</li>
<li>For <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery</li>
</ul>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<ul>
<li>about all of your medical conditions.</li>
<li>about all of the medicines you take.  NSAIDs and some other medicines can interact with each other and cause serious side effects.  <span class="Bold">Keep a list of your medicines to show to your healthcare provider and pharmacist.</span>
</li>
<li>if you are pregnant.  <span class="Bold">NSAID medicines should not be used by pregnant women late in their pregnancy. </span>
</li>
<li>if you are breastfeeding.  <span class="Bold">Talk to your healthcare provider.</span>
</li>
</ul>
<p><span class="Bold">What are the possible side effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<table width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">Serious side effects include:</span></td>
<td class="Rrule" align="left"><span class="Bold">Other side effects include:</span></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>high blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> from body <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>)</li>
<li>kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestine</li>
<li>low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></li>
<li>liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in people who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
</ul></td>
<td class="Rrule" align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>gas</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul></td>
</tr>
</tbody>
</table>
<table width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr class="First Toprule"><td align="left" colspan="2"><span class="Bold">Get emergency help right away if you have any of the following symptoms:</span></td></tr>
<tr class="Botrule Last">
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
</ul></td>
<td align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or side of your body</li>
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat</li>
</ul></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Stop your NSAID medicine and call your healthcare provider right away if you have any of the following symptoms:</span></p>
<table width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr class="First Last">
<td class="Lrule Rrule" align="left"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>more tired or weaker than usual</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>your skin or eyes look yellow</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>flu-like symptoms</li>
<li>vomit blood</li>
</ul></td>
<td class="Rrule" align="left"><ul class="Disc">
<li>there is blood in your bowel movement or it is black and sticky like tar</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms and legs, hands and feet</li>
</ul></td>
</tr></tbody>
</table>
<p>These are not all the side effects with NSAID medicines.  Talk to your healthcare provider or pharmacist for more information about NSAID medicines. </p>
<p>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</span></p>
<ul>
<li>Aspirin is an NSAID but it does not increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.  Aspirin can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain, stomach, and intestines.  Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestines.</li>
<li>Some of these NSAID medicines are sold in lower doses without a prescription (over-the-counter).  Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</li>
</ul>
<p><span class="Bold"><span class="Underline">NSAID medicines that need a prescription</span></span></p>
<table width="100%">
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="60%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Generic Name</th>
<th class="Rrule" align="left">Requires Prescription</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Celecoxib</td>
<td class="Rrule" align="left">Celebrex</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Diclofenac</td>
<td class="Rrule" align="left">Cataflam, Voltaren, Arthrotec (combined with misoprostol)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Difunisal</td>
<td class="Rrule" align="left">Dolobid</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Etodolac</td>
<td class="Rrule" align="left">Lodine, Lodine XL</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fenoprofen</td>
<td class="Rrule" align="left">Nalfon, Nalfon 200</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Flurbiprofen</td>
<td class="Rrule" align="left">Ansaid</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ibuprofen</td>
<td class="Rrule" align="left">Motrin, Tab-Profen, Vicoprofen (combined with hydrocodone), Combunox (combined with oxycodone), DUEXIS (combined with famotidine)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Indomethacin</td>
<td class="Rrule" align="left">Indocin, Indocin SR, Indo-Lemmon, Indomethagan</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ketoprofen</td>
<td class="Rrule" align="left">Orudis, Orudis KT, Oruvail</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ketorolac</td>
<td class="Rrule" align="left">Toradol</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Mefanamic Acid</td>
<td class="Rrule" align="left">Ponstel</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Meloxicam</td>
<td class="Rrule" align="left">Mobic</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nabumetone</td>
<td class="Rrule" align="left">Relafen</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Naproxen</td>
<td class="Rrule" align="left">Naprosyn, Anaprox, Anaprox DS, Prevacid NapraPAC (Prevacid copackaged with Naprosyn),Vimovo (combined with esomeprazole)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Oxaprozin</td>
<td class="Rrule" align="left">Daypro</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Enteric coated naproxen</td>
<td class="Rrule" align="left">EC-Naproxen, Naprelan</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Piroxicam</td>
<td class="Rrule" align="left">Feldene</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Sulindac</td>
<td class="Rrule" align="left">Clinoril</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Tolmetin</td>
<td class="Rrule" align="left">Tolectin, Tolectin DS, Tolectin 600</td>
</tr>
</tbody>
</table>
<p><span class="Bold">What is DUEXIS? </span></p>
<p>DUEXIS contains 2 medicines:</p>
<ol>
<li>Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID).  Please read the above information regarding the benefits and risks of NSAIDs, including ibuprofen, a component of DUEXIS.</li>
<li>Famotidine is a histamine 2 (H<span class="Sub">2</span>)-receptor antagonist, a medicine that may help reduce stomach acid.</li>
</ol>
<p>DUEXIS is a prescription medicine used to:</p>
<ul class="Disc">
<li>relieve signs and symptoms of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span></li>
<li>decrease the risk of developing <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> of the stomach and upper intestines (upper <span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">gastrointestinal ulcers</span>) in people who are taking ibuprofen for <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>.  DUEXIS was studied mostly in people less than 65 years of age and who did not have a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> of the stomach and upper intestines.</li>
</ul>
<p>It is not known if DUEXIS is safe or effective in children.</p>
<p><span class="Bold">Who should not take DUEXIS?</span></p>
<p><span class="Bold">Do not take DUEXIS:</span></p>
<ul>
<li>If you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> after taking aspirin or other NSAID medicine.</li>
<li>For <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery.</li>
<li>If you are in the late stages of pregnancy (after 30 weeks of pregnancy).</li>
<li>If you are allergic to any other histamine 2 (H<span class="Sub">2</span>)-receptor antagonist.</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking DUEXIS? </span></p>
<p><span class="Bold">Before you take DUEXIS, tell your healthcare provider if you: </span></p>
<ul class="Disc">
<li>have high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)</li>
<li>have heart problems</li>
<li>have a history of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcers</span></li>
<li>have or had <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</li>
<li>have liver or kidney problems</li>
<li>have <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> or Crohn's disease (<span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> or IBD)</li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. DUEXIS should not be used by pregnant women late their pregnancy. <span class="Bold"> See "<a href="#What">What is the most important information I should know about DUEXIS</a>?"  </span>
</li>
<li>are breast-feeding or plan to breast-feed. DUEXIS can pass into your milk and may harm your baby. You should not breast-feed while taking DUEXIS. Talk to your healthcare provider about the best way to feed your baby if you take DUEXIS.</li>
</ul>
<p>Tell your healthcare provider about all of the medicines you take including prescription and nonprescription medicines, vitamins, and herbal supplements.  Since DUEXIS contains ibuprofen, talk to your healthcare provider before taking any other NSAID containing products.</p>
<p>Using DUEXIS with other medicines can cause serious side effects.  DUEXIS may affect the way other medicines work and other medicines may affect how DUEXIS works.</p>
<p>Especially, tell your doctor if you take:</p>
<dl>
<dt> </dt>
<dd><ul class="Disc">
<li>Aspirin</li>
<li>Warfarin (Coumadin)</li>
</ul></dd>
</dl>
<p><span class="Bold">How should I take DUEXIS?</span></p>
<ul class="Disc">
<li> Take DUEXIS exactly as your healthcare provider tells you to take it.</li>
<li>Your healthcare provider will tell you how many DUEXIS to take and when to take them.</li>
<li>Do not stop DUEXIS without first talking to your healthcare provider.</li>
<li>Swallow DUEXIS tablets whole.  Do not crush, split or chew DUEXIS tablets.</li>
<li>If you forget to take a dose of DUEXIS, take it as soon as you remember. If it is almost time for your next dose, do not take the missed dose. Take the next dose on time. Do not take 2 doses at one time to make up for a missed dose.</li>
<li>If you take too much DUEXIS, tell your healthcare provider or go to the nearest hospital emergency room right away.</li>
</ul>
<p>If you take more DUEXIS than your doctor recommends, call your Poison Control Center at 1-800-222-1222.</p>
<ul class="Disc"><li>  Your doctor may do certain tests from time to time to check you for side effects of DUEXIS.</li></ul>
<p><span class="Bold">What are the possible side effects of DUEXIS?</span></p>
<p><span class="Bold">DUEXIS may cause serious side effects. </span></p>
<p>See "<a href="#What">What is the most important information I should know about DUEXIS?</a>"</p>
<ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart Attack</span></span>. If you have heart disease you may be at risk for a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> while taking DUEXIS. Call your healthcare provider or get medical help right away if you have any of these signs and symptoms: 							<table width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center" colspan="2"><span class="Bold">Signs and symptoms of a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></span></td></tr>
<tr class="Botrule Last">
<td align="left"><ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> of the face, arm or leg, especially on one side of the body</li>
<li>sudden <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, trouble speaking or understanding</li>
</ul></td>
<td align="left"><ul class="Square">
<li>sudden trouble seeing in one or both eyes</li>
<li>sudden trouble walking, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, loss of balance or coordination</li>
<li>sudden, severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
</ul></td>
</tr>
</tbody>
</table>
<table width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center" colspan="2"><span class="Bold">Signs and symptoms of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart Attack</span></span></td></tr>
<tr class="Botrule Last">
<td align="left"><ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span> in the center of your chest that lasts for more than few minutes, or that goes away or comes back</li>
<li><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span> that feels like uncomfortable pressure or squeezing.</li>
<li>chest fullness or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul></td>
<td align="left"><ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in your arms, back, neck, jaw or stomach</li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> with or without <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span></li>
<li>break out in a <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">cold sweat</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </li>
</ul></td>
</tr>
</tbody>
</table>
</li></ul>
<ul class="Disc">
<li>
<span class="Bold">New or worsening high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>). </span>Your healthcare provider should check your blood pressure while you are taking DUEXIS.</li>
<li>
<span class="Bold">Heart problems </span>such as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Tell your healthcare provider about any <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your body, hands or feet, sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or trouble breathing.</li>
<li>
<span class="Bold">Active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. </span>Tell your doctor if you have signs of active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> including:<ul class="Square">
<li>passing black sticky bowel movements (stools)</li>
<li>having <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up blood or dark particles that look like coffee grounds</li>
</ul>
</li>
<li>
<span class="Bold">Kidney problems. </span>Long term use of NSAIDS, including ibuprofen which is a medicine in DUEXIS can cause kidney problems. Your healthcare provider should do blood test to check your kidneys. </li>
<li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. </span>Tell your healthcare provider or get medical help right away if you get:<ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your lips, tongue, or face</li>
<li><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li>problems breathing or swallowing </li>
</ul>
</li>
<li>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. </span>NSAIDS, including ibuprofen which is a medicine in DUEXIS can cause a serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> called <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> or other serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> that may affect any part of your body. These serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may be life threatening and you may need to be treated in a hospital. Stop taking DUEXIS and call your healthcare provider right away if you have any of these symptoms:<table width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr class="First Last Toprule">
<td align="left"><ul class="Square">
<li> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span></li>
<li> <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span></li>
<li> <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li> <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> on your skin</li>
<li> <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> or sores in your mouth</li>
<li><span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of your skin</li>
</ul></td>
<td align="left"><ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li>muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span></li>
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, hands, or soles of your feet</li>
</ul></td>
</tr></tbody>
</table>
</li>
</ul>
<ul class="Disc"><li>
<span class="Bold">Liver problems. </span>Tell your healthcare provider right away if you have any of these following symptoms of liver problems:<ul class="Square">
<li>dark (tea colored) urine</li>
<li>yellowing of your skin or whites of your eyes</li>
<li>light-colored bowel movements (stools)</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (feeling sick to your stomach)</li>
<li>feel unwell or like you have the flu </li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> on your right side below your ribs</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li> loss of appetite</li>
</ul>
</li></ul>
<ul>
<li>
<span class="Bold">Low red blood cell count (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>). </span>Symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> include <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span>. </span> Ibuprofen, one of the medicines in DUEXIS may cause <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, a serious brain problem. Call your healthcare provider right away if you have any of the following symptoms of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>:<table width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr class="First Last Toprule">
<td align="left"><ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiff neck</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
</ul></td>
<td align="left"><ul class="Square">
<li>unusual sensitivity to light</li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span></li>
<li><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></li>
</ul></td>
</tr></tbody>
</table>
</li>
</ul>
<ul>
<li>
<span class="Bold">Eye problems. </span>Tell your healthcare provider if you develop blurred or decreased vision, changes in color vision, or any other problems with your eyes.</li>
<li>
<span class="Bold">Gastrointestinal problems.</span> Tell your healthcare provider right away if you have any of these following symptoms of gastrointestinal problems: 						<table width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr class="First Last Toprule">
<td align="left"><ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </li>
<li>upper stomach (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul></td>
<td align="left"><ul class="Square">
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></li>
<li><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></li>
</ul></td>
</tr></tbody>
</table>
</li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of DUEXIS. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store DUEXIS? </span></p>
<ul>
<li>   Store DUEXIS at 59°F to 86°F (15°C to 30°C).</li>
<li>   Keep DUEXIS in the original container and keep the bottle tightly closed.</li>
<li>   Keep DUEXIS dry.</li>
</ul>
<p><span class="Bold">Keep DUEXIS and all medicines out of the reach of children. </span></p>
<p><span class="Bold">General information about DUEXIS.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in this Medication Guide. Do not use DUEXIS for a condition for which it was not prescribed. Do not give DUEXIS to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about DUEXIS. If you would like more information, ask your healthcare provider. You can ask your healthcare provider or pharmacist for information that is written for healthcare professionals.</p>
<p>For more information, go to www.DUEXIS.com or call 1-866-479-6742</p>
<p><span class="Bold">What are the ingredients in DUEXIS? </span></p>
<p><span class="Bold">Active ingredients</span>: ibuprofen and famotidine</p>
<p><span class="Bold">Inactive ingredients: </span>microcrystalline cellulose, anhydrous lactose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, purified water, povidone, titanium dioxide, polyethylene glycol, polysorbate 80, polyvinyl alcohol, talc, FD&amp;C Blue #2/Indigo Carmine Aluminum Lake and FD&amp;C Blue #1/Brilliant Blue FDF Aluminum Lake</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold">Horizon Pharma USA, Inc.<br>520 Lake Cook Road, Ste. 520<br>Deerfield, Illinois 60015</span></p>
<p>November 2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 90 Tablet Bottle Label</span></p>
<p>NDC 75987-010-03</p>
<p><span class="Bold">DUEXIS<span class="Sup">®</span></span></p>
<p><span class="Bold">(ibuprofen and famotidine) Tablets<br>800 mg/26.6 mg</span></p>
<p><span class="Bold">90 </span>Tablets</p>
<p>Rx ONLY</p>
<p><span class="Bold">ATTENTION PHARMACIST: </span>Dispense<br>attached Medication Guide to each patient.</p>
<p><span class="Bold">HORIZON</span><br>PHARMA</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 90 Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=558b9f26-37b2-423b-932d-25a37afe57ec&amp;name=duexis-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DUEXIS 		
					</strong><br><span class="contentTableReg">ibuprofen and famotidine tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:75987-010</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Ibuprofen</strong> (Ibuprofen) </td>
<td class="formItem">Ibuprofen</td>
<td class="formItem">800 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Famotidine</strong> (Famotidine) </td>
<td class="formItem">Famotidine</td>
<td class="formItem">26.6 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE No. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE No. 1</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Light Blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">HZT</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:75987-010-03</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:75987-010-72</td>
<td class="formItem">9  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022519</td>
<td class="formItem">04/29/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Horizon Pharma Inc.
							(964613413)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BASF Corporation</td>
<td class="formItem"></td>
<td class="formItem">014403088</td>
<td class="formItem">API MANUFACTURE(75987-010)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Dr. Reddy's Laboratories, Ltd.</td>
<td class="formItem"></td>
<td class="formItem">650443471</td>
<td class="formItem">ANALYSIS(75987-010)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">sanofi-aventis U.S.</td>
<td class="formItem"></td>
<td class="formItem">011330557</td>
<td class="formItem">PACK(75987-010), LABEL(75987-010)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Valeant Pharmaceuticals International</td>
<td class="formItem"></td>
<td class="formItem">245141858</td>
<td class="formItem">PACK(75987-010), MANUFACTURE(75987-010)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">WelchDry</td>
<td class="formItem"></td>
<td class="formItem">606201283</td>
<td class="formItem">MANUFACTURE(75987-010)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">A+ Secure Packaging, LLC</td>
<td class="formItem"></td>
<td class="formItem">963589036</td>
<td class="formItem">RELABEL(75987-010)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Winthrop Industrie</td>
<td class="formItem"></td>
<td class="formItem">297676475</td>
<td class="formItem">MANUFACTURE(75987-010), PACK(75987-010)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>57ac50bb-550a-49b4-8947-0f5f2e1d7242</div>
<div>Set id: 558b9f26-37b2-423b-932d-25a37afe57ec</div>
<div>Version: 8</div>
<div>Effective Time: 20150724</div>
</div>
</div> <div class="DistributorName">Horizon Pharma Inc.</div></p>
</body></html>
